These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 28960793)
1. Real-world effect of ribavirin on quality of life in HCV-infected patients receiving interferon-free treatment. Höner Zu Siederdissen C; Schlevogt B; Solbach P; Port K; Cornberg M; Manns MP; Wedemeyer H; Deterding K Liver Int; 2018 May; 38(5):834-841. PubMed ID: 28960793 [TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. Mandorfer M; Payer BA; Scheiner B; Breitenecker F; Aichelburg MC; Grabmeier-Pfistershammer K; Rieger A; Trauner M; Peck-Radosavljevic M; Reiberger T Liver Int; 2014 Jan; 34(1):69-77. PubMed ID: 23890125 [TBL] [Abstract][Full Text] [Related]
3. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study. Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225 [TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Younossi ZM; Stepanova M; Nader F; Jacobson IM; Gane E; Nelson D; Lawitz E; Hunt SL Hepatology; 2014 Jun; 59(6):2161-9. PubMed ID: 24710669 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program. Gray E; O'Leary A; Bergin C; Cannon M; Courtney G; Crosbie O; De Gascun CF; Fanning LJ; Feeney E; Houlihan DD; Kelleher B; Lambert JS; Lee J; Mallon P; McConkey S; McCormick A; McKiernan S; McNally C; Murray F; Sheehan G; Stewart S; Walsh C; Norris S; Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):593-601. PubMed ID: 28276815 [TBL] [Abstract][Full Text] [Related]
6. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Mira JA; García-Rey S; Rivero A; de los Santos-Gil I; López-Cortés LF; Girón-González JA; Téllez F; Márquez M; Merino D; Ríos-Villegas MJ; Macías J; Rivero-Juárez A; Pineda JA Clin Infect Dis; 2012 Dec; 55(12):1719-26. PubMed ID: 22955435 [TBL] [Abstract][Full Text] [Related]
7. Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals. van Tilborg M; Lieveld FI; Smolders EJ; van Erpecum KJ; de Kanter CTMM; Maan R; van der Valk M; Arends JE; Dofferhoff ASM; Blokzijl H; Bijmolen M; Drenth JPH; de Knegt RJ; Burger DM; Aliment Pharmacol Ther; 2017 Nov; 46(9):864-872. PubMed ID: 28881031 [TBL] [Abstract][Full Text] [Related]
8. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Mira JA; Rivero-Juárez A; López-Cortés LF; Girón-González JA; Téllez F; de los Santos-Gil I; Macías J; Merino D; Márquez M; Ríos-Villegas MJ; Gea I; Merchante N; Rivero A; Torres-Cornejo A; Pineda JA; Clin Infect Dis; 2013 Jun; 56(11):1646-53. PubMed ID: 23429381 [TBL] [Abstract][Full Text] [Related]
9. Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study. Kovari H; Russmann S; Ledergerber B; Müller D; Rotger M; Velli P; Cavassini M; Ambrosioni J; Bregenzer A; Stöckle M; Bernasconi E; Rauch A; Speck RF; PLoS One; 2015; 10(7):e0133879. PubMed ID: 26218843 [TBL] [Abstract][Full Text] [Related]
10. French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: The Effect on Patient-Reported Outcomes. Cacoub P; Bourliere M; Asselah T; De Ledinghen V; Mathurin P; Hézode C; Henry L; Stepanova M; Younossi ZM Value Health; 2018 Oct; 21(10):1218-1225. PubMed ID: 30314623 [TBL] [Abstract][Full Text] [Related]
11. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients. Macías J; Rivero A; Cifuentes C; Camacho A; Neukam K; Rivero-Juárez A; Mira JA; Torre-Cisneros J; Gómez-Mateos J; Pineda JA Enferm Infecc Microbiol Clin; 2013; 31(7):424-9. PubMed ID: 23453582 [TBL] [Abstract][Full Text] [Related]
12. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy. Bruno R; Cariti G; Nasta P; Capetti A; Ravasio V; Galli M; Raise E; Palmieri G; Iannacone C; Puoti M Liver Int; 2015 Jan; 35(1):120-9. PubMed ID: 25041136 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation. Ciesek S; Proske V; Otto B; Pischke S; Costa R; Lüthgehetmann M; Polywka S; Klempnauer J; Nashan B; Manns MP; von Hahn T; Lohse AW; Wedemeyer H; Mix H; Sterneck M Transpl Infect Dis; 2016 Jun; 18(3):326-32. PubMed ID: 26988272 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638 [TBL] [Abstract][Full Text] [Related]
17. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort. Steinebrunner N; Sprinzl MF; Zimmermann T; Wörns MA; Zimmerer T; Galle PR; Stremmel W; Eisenbach C; Stein K; Antoni C; Schattenberg JM; Pathil A BMC Gastroenterol; 2015 Aug; 15():97. PubMed ID: 26239732 [TBL] [Abstract][Full Text] [Related]
18. Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report. Kawaoka T; Imamura M; Kan H; Fujino H; Fukuhara T; Kobayashi T; Honda Y; Naeshiro N; Hiramatsu A; Tsuge M; Hayes CN; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Tashiro H; Ohdan H; Chayama K Transplant Proc; 2015 Apr; 47(3):809-14. PubMed ID: 25891736 [TBL] [Abstract][Full Text] [Related]
19. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin. Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544 [TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data. Pyrsopoulos N; Trilianos P; Lingiah VA; Fung P; Punnoose M Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):761-765. PubMed ID: 29481384 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]